About this trial
The objectives of the intervention are to counteract the progression of cognitive decline, enhance the intrinsic abilities of users and support the well-being of elderly people with mild cognitive impairment (MCI) through a socio-technical intervention that includes cognitive stimulation, technology and robotics.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
diagnosis of Mild Cognitive Impairment;
MoCA ranged 21 - 27;
Geriatric Depression Scale 5 items (GDS-5items) ≤ 1
Disqualifiers
Use of active implantable or non-implantable medical devices;
Nickel allergy;
Myocardial infarction or stroke within 6 months;
Painful arthritis, spinal stenosis, amputation, painful foot lesions, or neuropathy that limits balance and mobility;
Trial design
Parallel
Treatments tested in this trial
socio-technical intervention
Other interventionA daily cognitive stimulation at home with specific software (Brainer) and 1 group session per week. Furthermore, each participant will receive the NAO robot at home.
Usual care
Other interventionThe subjects will receive a booklet containing information and activities on well-being. They will be invited to do whatever they wish with the information booklet and the proposed exercises, as they would do outside the framework of the experiment. In any case, they will be free to read and do the proposed exercises.
Treatment groups
Trial outcomes
Primary outcomes
cognitive capabilities of older people with MCI
It will be assessed through the Montreal Cognitive Assessment (MoCA). The MoCA is a one-page 30-point test administered in approximately 10 minutes. The MoCA assesses several cognitive domains: the short-term memory recall task (5 points), visuospatial abilities (4 points), alternation task (1 point), verbal abstraction task (1 point), attention, concentration, and working memory (6 points), language (6 points), abstract reasoning (2 points), and orientation to time and place (6 points). A score of 26 or above is typically considered within the normal range; scores between 18 and 25 may suggest mild cognitive impairment; scores between 10 and 17 may indicate moderate cognitive impairment; scores below 10 may indicate severe cognitive impairment.
Secondary outcomes
Fragility
It will be assessed by the Clinical Frailty Scale (CFS). This descriptive scale divides the older participants into 9 classes based on the information provided by them and their relatives: between 1 and 3 the patient is non-frail, pre-frail if 4, he is frail from 5 to 9.
Health related quality of life
The health related quality of life will be evaluated by EQ-5D-5L. The scale consists of five dimensions: mobility, independence, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, mild problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health status by ticking the box corresponding to the most appropriate statement in each of the five dimensions. The numbers from the five dimensions can be combined into a 5-digit number that describes the health status of the participant. A person reporting "no problems" in all five dimensions would have a health state profile of 11111 (representing full health). A person with "slight problems with mobility (2), no problems with self-care (1), moderate problems with usual activities (3), severe pain/discomfort (4), and no anxiety/depression (1)" would have a health state profile of 21341. The "worst possible health state" would be 55555.
Psychological Wellbeing
The Psychological Wellbeing Scale (PWB) consists of several subscales (self acceptance, positive relationships with others, autonomy, environmental mastery, purpose in life, and personal growth) that measures six aspects of wellbeing and happiness. Individuals respond to the 42 items. Each of the 42 items is rated on a 7-point Likert scale, ranging from 1 ("Strongly disagree") to 7 ("Strongly agree"). The total score can range from 42 to 294, with higher scores indicating greater overall psychological well-being.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Istituto Nazionale di Ricovero e Cura per Anziani
Lead sponsor
Ministry of Health, Italy
Collaborator